Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Allergic Rhinitis | Study protocol

Chinese herbal medicine bi min fang for allergic rhinitis: protocol for a double-blind, double-dummy, randomized controlled trial

Authors: Qiulan Luo, Shiqing Zhou, Xiaoshan Li, Qubo Chen, Wenmin Lin, Liming Lu, Hua Li, Caifeng Chen, Wenyong Chen, Yunying Li

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

People with allergic rhinitis (AR) often seek help from Chinese medicine due to dissatisfaction with conventional treatments. Lung-spleen qi deficiency syndrome (LSQDS) is the most common type of AR, and the Chinese herbal medicine formula bi min fang (BMF) is commonly prescribed for AR patients with LSQDS. However, direct evidence supporting its efficacy and safety is not available, and its potential mechanism of action remains unclear.

Methods/design

This paper presents a double-blind, double-dummy, randomized controlled trial. After a 2-week run-in period, 80 AR patients with LSQDS will be recruited and randomly allocated to the BMF group or the control group in a 1:1 ratio. The patients in the BMF group will receive BMF and the placebo for levocetirizine hydrochloride orally, while the control group participants will receive levocetirizine hydrochloride and the placebo for BMF orally. All participants will receive 4 weeks of treatment and 12 weeks of follow-up.
The primary outcome is a change in the Total Nasal Symptom Score (TNSS). Secondary outcomes include changes in scores for the standard version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)), and visual analog scale (VAS); changes in serum levels of the cytokines interleukin-4, interferon-γ, transforming growth factor β-1, and interleukin-17; and changes in the gut microbiota composition in the stool. The TNSS, RQLQ(S), and VAS will be recorded at the beginning of, middle of and after the treatment period and at the end of each month in the 3-month follow-up period. Blood and stool samples will be collected at baseline and the end of the treatment. The aforementioned four cytokines will be detected in the serum using enzyme-linked immunosorbent assays, and the stool gut microbiota will be detected using 16S ribosomal ribonucleic acid sequencing. Any side effects of the treatment will be recorded.

Discussion

The results of this trial will provide consolidated evidence of the effect of BMF on AR and the potential mechanism by which BMF acts. This study will be the first to explore the mechanism of action of Chinese herbal medicine on the gut microbiota in AR.

Trial registration

Chinese Clinical Trial Registry, ChiCTR-IPR-17010970. Registered on 23 March 2017.
Appendix
Available only for authorised users
Literature
1.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis andits impact on asthma (ARIA) 2008 update. Allergy. 2008;63(Suppl 86):8–160.CrossRef
2.
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Walter Canonica G, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.CrossRef
3.
Zheng M, Wang XD, Bo MY, Wang KJ, Zhao Y, He F, et al. Prevalence of Allergic Rhinitis among adults in urban and rural areas of China: A population-based cross-sectional survey. Allergy Asthma Immunol Res. 2015;7(2):148–57.CrossRef
4.
Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;51(1):6–24 [Article in Chinese].
5.
Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(Suppl 2):12–6.
6.
Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Head Neck Surg. 2015;152(Suppl 1):1–43.
7.
Kern J, Bielory L. Complementary and alternative therapy (CAM) in the treatment of Allergic Rhinitis. Curr Allergy Asthma Rep. 2014;14(12):479.CrossRef
8.
Chan RY, Chien WT. The effects of two Chinese herbal medicinal formulae vs placebo controls for treatment of allergic rhinitis: a randomised controlled trial. Trials. 2014;15:216.CrossRef
9.
Hu GR, Wlls RS, Bass D, Bullock R, Grayson D, Jones M. The Chinese herbal formulation Biminne in management of perennial allergic rhinitis a randomized, double-blind, placebo-controlled, 12-week clinical trial. Ann Allergy Asthma Immunol. 2002;88(5):478–87.CrossRef
10.
Zhao Y, Woo KS, Ma KH, van Hansselt CA, Wong KC, Cheng KF, et al. Treatment of perennial allergic rhinitis using Shi-Bi-Lin, a Chinese herbal formula. J Ethnopharmacol. 2009;122(1):100–5.CrossRef
11.
Wang SJ, Tang QF, Qian W, Fan Y. Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistent allergic rhinitis. Allergy. 2012;67(5):583–92.CrossRef
12.
Qiu BS, Wang SZ, Zhong YP, Mu RY. Correlation between syndrome types and clinical features of allergic rhinitis. J Tradit Chin Med. 2004;45(5):373–5 [Article in Chinese].
13.
Song WJ, Li X, Xie Q. Analysis of traditional Chinese medicine syndrome differentiation in 300 cases of allergic rhinitis. Chin Comm Doc. 2012;14(8):219 [Article in Chinese].
14.
15.
Qi W. Distribution investigation of related pathogenic factors and traditional Chinese medicine clinical syndrome types of allergic rhinitis. Guid J Tradit Chin Med Pharm. 2013;10(31):125–8 [Article in Chinese].
16.
Liu ZW, Zhang CH, Ji J, Hong Y, Ma XF, Ma J. Roughset analysis of indexes for objectification syndrome differentiation and classification of allergic rhinitis. Liaoning J Tradit Chin Med. 2013;40(11):2227–30 [Article in Chinese].
17.
Yen HR, Liang KL, Huang TP, Fan JY, Chang TT, Sun MF. Characteristics of traditional Chinese medicine use for children with allergic rhinitis: a nationwide population-based study. Int J Pediatr Otorhinolaryngol. 2015;79(4):591–7.CrossRef
18.
Bi Qiu (allergic rhinitis). In: China Association of Chinese Medicine. Diagnosis and treatment guidelines in traditional Chinese medicine for common otolaryngology disease. Beijing: China Press of Traditional Chinese Medicine; 2012. p. 17–8. [Article in Chinese].
19.
Luo QL. A brief discussion on the application of the theory “Piwei Lun” to treat nasal diseases. J New Chi Med. 2012;43(5):146–7 [Article in Chinese].
20.
Yang SH, Yu CL. Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis. J Ethnopharmacol. 2008;115(1):104–9.CrossRef
21.
Fang XY, Feng SS, Li Y, Zhang XT, Zhu Y, Zhan G. Clinical efficacy of yu ping feng capsule in treatment of allergic rhinitis and its safety evaluation. Chin Arch Tradit Chin Med. 2014;32(10):2556–8 [Article in Chinese].
22.
Gao J, Li J, Shao X, Jin Y, Lü XW, Ge JF, et al. Anti-inflammatory and immuno-regulatory effects of total glucosides of Yupingfeng powder. Chin Med J. 2009;122(4):1636–41.PubMed
23.
Frick JS, Autenrieth IB. The gut microflora and its variety of roles in health and disease. Curr Top Microbiol Immunol. 2013;358:273–89.PubMed
24.
Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128(3):646–52.CrossRef
25.
Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-Browne RM, Tang MLK. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr Allergy Immunol. 2012;23(7):674–81.CrossRef
26.
Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. 2014;44(6):842–50.CrossRef
27.
Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol. 2012;129(2):434–40.CrossRef
28.
Melli LC, do Carmo-Rodriues M, Araújo-Filho HB, Solé D, de Morais MB. Intestinal microbiota and allergic diseases: A systematic review. Allergol Immunopathol (Madr). 2016;44(2):177–88.CrossRef
29.
Kubota A, He F, Kawase M, Harata G, Hiramatsu M, Iino H. Diversity of intestinal bifidobacteria in patients with Japanese Cedar Pollinosis and possible influence of probiotic intervention. Curr Microbiol. 2011;62(1):71–7.CrossRef
30.
Ouwehand AC, Nermes M, Collado MC, Rautonen N, Salminen S, Isolauri E. Specific probiotics alleviate allergic rhinitis during the birch pollen season. World J Gastroenterol. 2009;15(26):3261–8.CrossRef
31.
Odamaki TXJ, Iwabuchi N, Sakamoto M, Takahashi N, Kondo S, Iwatsuki K, et al. Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during the pollen season and influence of probiotic intake. J Investig Allergol Clin Immunol. 2007;17(2):92–100.PubMed
32.
Güvenc IA, Muluk NB, Mutlu FS, Eski E, Altintoprak N, Oktemer T, et al. Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta-analysis. Am J Rhinol Allergy. 2016;30(5):157–75.CrossRef
33.
Vliagoftis H, Kouranos VD, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma:systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008;101(6):570–9.CrossRef
34.
Costa DJ, Marteau P, Amouyal M, Poulsen LK, Hamelmann E, Cazaubiel M, et al. Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). Eur J Clin Nutr. 2014;68(5):602–7.CrossRef
35.
Nagata Y, Yoshida M, Kitazawa H, Araki E, Gomyo T. Improvements in seasonal allergic disease with Lactobacillus plantarum No. 14. Biosci Biotechnol Biochem. 2010;74(9):1869–77.CrossRef
36.
Xu J, Chen HB, Li SL. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev. 2017;37(5):1140–85.CrossRef
37.
Ivory K, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C. Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy. 2008;38(8):1282–9.CrossRef
38.
Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–32.CrossRef
39.
Lei ZQ. Science of Chinese Materia Medica. 1st ed. Shanghai: Shanghai Scientific and Technical Publishers; 1995. [Textbook in Chinese]
40.
Pfaar O, Demoly P, Gerth van Wijk RG, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–67.CrossRef
41.
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83.CrossRef
42.
Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104(2Pt1):364–9.CrossRef
43.
Bousquet PJ, Combescure C, Neukirch F, Klossek J, Mechin H, Daures JP, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367–72.CrossRef
44.
Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;185(Suppl 5):147–334.CrossRef
45.
Noma T, Helper T. cell paradigm Th17 and regulatory T cells involved in autoimmune inflammatory disorders, pathogen defense and allergic diseases. Jpn J Clin Immunol. 2010;33(5):262–71 [Article in Japanese].CrossRef
46.
Li L, Bai H. Clinical observation of yu chan wei fei pill in treating allergic rhinitis. Chin J Integr Trad West Med. 2012;32(1):126–8 [Article in Chinese].
47.
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428–33.CrossRef
48.
Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68(1):1–7.CrossRef
49.
Deng TT, Chen Q, Guo ZQ. Diagnostics of Traditional Chinese Medicine. 2nd ed. Shanghai: Shanghai Scientific and Technical Publishers; 2006. p. 6–7. [Textbook in Chinese]
Metadata
Title
Chinese herbal medicine bi min fang for allergic rhinitis: protocol for a double-blind, double-dummy, randomized controlled trial
Authors
Qiulan Luo
Shiqing Zhou
Xiaoshan Li
Qubo Chen
Wenmin Lin
Liming Lu
Hua Li
Caifeng Chen
Wenyong Chen
Yunying Li
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-3151-0

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Research

Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices

Study protocol

Hygiene protocols for the treatment of denture-related stomatitis: local and systemic parameters analysis - a randomized, double-blind trial protocol

Study protocol

A novel mindful-compassion art therapy (MCAT) for reducing burnout and promoting resilience for end-of-life care professionals: a waitlist RCT protocol

Methodology

Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial

Study protocol

The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT)

Study protocol

A mindfulness and compassion-based program applied to pregnant women and their partners to decrease depression symptoms during pregnancy and postpartum: study protocol for a randomized controlled trial